Company Overview and News
Grubhub (GRUB - Free Report) earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, delivering an average positive earnings surprise of 25.6%. With expected long-term earnings per share growth rate of 25% and a market cap of $12.99 billion, it seems to be a stock that investors should keep in their portfolio for now. Let’s take a look at the factors that have been driving the company’s performance.
GRPN YUM YELP GRUB
Grubhub (GRUB - Free Report) recently completed the acquisition of LevelUp, which manages digital ordering and payment solutions for national and regional restaurants, for $390 million in cash. LevelUp has a customer base comprising the likes of Roti, Pret a Manger, Zaxby's and Just Salad, among others. The acquisition will add more than 200 customers with robust point-of-sale integrations. Grubhub expects the LevelUp transaction to contribute revenues of approximately $2 million to third-quarter results.
GRPN YUM CY YELP GRUB
Stocks were indicated to open marginally higher on Friday, but not so much that the direction of this day looked set. U.S. equity indexes remain near all-time highs at a time that most international markets are not close to their highs. One issue that stands out to U.S. investors is that they have seen less upside from buying on market pullbacks than in prior years. Investors also need to consider how they want to have their investments positioned for the rest of 2018.
WFCNP YELP ADBE WMT WFC GLW ANGI COST GRUB DHI DNKN TRI
Chinese startup Meituan Dianping raised about $4.2 billion from its initial public offering in Hong Kong, according to people familiar with the situation, defying a weak market to show investors remain keen on fast-growing technology companies.
GRPN GRUB YELP 0700
2018-09-11 zacks - 1
PayPal (PYPL - Free Report) saw its stock price climb over 2% Tuesday after the company announced its Funds Now instant payment feature for businesses. PayPal’s latest move helps it better compete in a crowded digital payment industry. The question for investors is should they consider buying PYPL stock at the moment?
TGT SQ GRUB AAPL EBAY
Groupon, Inc. (GRPN - Free Report) recently entered into an extended strategic relationship with MLBAM’s privately owned subsidiary, Tickets.com. Per the partnership, Groupon will be able to furnish robust ticketing experiences to major ticketing clients of Tickets.com. Tickets.com’s Registered Developer Program enables validated third-party offerings to integrate with its ProVenue ticketing platform.
GRPN AMZN GRUB RSG
Wells Fargo & Co. has fired or suspended more than a dozen employees in its investment bank and is investigating dozens of others over alleged violations of the company’s expense policy regarding after-hours meals, according to people familiar with the matter.
WFC WFCNP SQ SQNXF GRUB
Shares of PayPal (PYPL - Free Report) surged over 2.2% to touch a new all-time high Wednesday on the back of an analyst upgrade and momentum following the slow rollout of its newly redesigned app.
SQ GRUB AAPL EBAY
A month has gone by since the last earnings report for GrubHub (GRUB - Free Report) . Shares have added about 1.8% in that time frame, outperforming the S&P 500.
Investors interested in Computer and Technology stocks should always be looking to find the best-performing companies in the group. GrubHub (GRUB - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? One simple way to answer this question is to take a look at the year-to-date performance of GRUB and the rest of the Computer and Technology group's stocks.
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to GRUB / GrubHub Inc. on message board site Silicon Investor.
as of ET